格列奈类胰岛素促泌剂的联合用药及在2型糖尿病合并肾功能不全患者中的应用  

Combination Therapy of Insulinotropic Agents Glinides and Its Application on Type 2 Diabetes with Renal Insufficiency

作　　者：李全民 LI Quanmin(PLA Rocket Force General Hospital,Beijing 100088,China)

机构地区：[1]火箭军特色医学中心,北京100088

出　　处：《药品评价》2023年第8期920-923,共4页Drug Evaluation

摘　　要：格列奈类药物属于非磺脲类胰岛素促泌剂,是一类重要的口服降糖药物之一。格列奈类药物对餐后血糖的有效控制,使其在与基础胰岛素或其他机制互补的口服降糖药联合应用时,能获得空腹血糖和餐后血糖的良好控制,并不增加低血糖风险;同时,格列奈类药物适用于特殊糖尿病人群,特别是合并肾功能不全的患者,因其几乎不经过肾脏代谢,不增加肾脏负担,与其他口服降糖药相比具有明显优势。因此,合理选择及使用格列奈类药物对临床治疗2型糖尿病合并肾功能不全具有重要意义。Glinides,the well-known non-sulfonylurea insulin secretagogues,are major components of oral antidiabetic drugs.Glinides which have priority in controlling the post-prandial glucose,in combination with basal insulin or other oral antidiabetic drugs responsible in complementary mechanisms would achieve mutual synergic benefits in controlling fasting and post-prandial glucose,without increasing the risk of hypoglycemia.Because glinides are merely eliminated through kidneys and do not increase the renal overload,glinides could gain significant advantages over other oral antidiabetic drugs.They are favorable to special diabetic populations,e.g.,patients with renal insufficiency.Herein,rational selection and application of glinides play a significant role in clinical therapy for type 2 diabetes.

关 键 词：糖尿病 胰岛素促泌剂 格列奈类药物 联合治疗 肾功能不全 

分 类 号：R587.2[医药卫生—内分泌] R692[医药卫生—内科学]